Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses...
16 insider purchases on record · latest filing 2023-08-16.
Insiders have also filed 2 sale transactions at INDP.